Moderna (NasdaqGS:MRNA) appointed Juan Andres as its first Chief Operating Officer as it reshapes its leadership structure.

Moderna (NasdaqGS:MRNA) entered high-level investment talks with the UAE government on advanced pharmaceutical manufacturing ...

Modernas cancer-vaccine program is driving renewed market attention. Its mRNA platform extends beyond COVID-19 vaccines. Clinical progress remains central to the companys evolving story. Modernas ...

Post-pandemic, investors bailed on what was once one of the most-followed biotech stocks amid pessimism about the company's ability to further monetize its mRNA technology. But then, as the company ...

Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in ...

Warner Bros. Discovery drops from Nasdaq 100 and S&P 500 as $81B Paramount merger closes. Moderna and Twilio fill the vacancies next week.

Moderna, Inc. MRNA shares are trending on Thursday night. Shares of the Massachusetts-based biotechnology and pharmaceutical company edged 0.087% higher to $194.99 in after-hours trading on Thursday.

Moderna ( ) just unveiled an update. On September 1, 2026, Moderna completed a $3.0 billion private offering of 0.00% Convertible Senior Notes due 2032, issued as senior unsecured ...

Moderna (MRNA) is rated Sell due to overextended valuation post-melanoma Phase 3 trial news, with a fair value estimate near $110 versus ~$145 trading price. Current market pricing assumes de-risked ...